| http://www.w3.org/ns/prov#value | - To investigate this further, the INFORM study was an open-label, non-comparative phase II study of gefitinib (Iressa, ZD1839; AstraZeneca, Wilmington, DE, USA) 250???mg daily in combination with 5-fluorouracil (5-FU administered as an intravenous 400???mg???m???2 bolus injection followed by 2800???mg???m???2 infusion over 46???h and folinic acid administered as a 350???mg infusion over 2???h) ever
|
